Pharmacyclics LLC - Company Profile
Powered by
All the data and insights you need on Pharmacyclics LLC in one report.
- Save hours of research time and resources with
our up-to-date Pharmacyclics LLC Strategy Report
- Understand Pharmacyclics LLC position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pharmacyclics LLC (Pharmacyclics), a subsidiary of AbbVie Inc, is a biopharmaceutical company which focuses on the development and commercialization of small-molecule medicines for the treatment of cancer and immune-mediated diseases. The company’s marketed product includes Imbruvica is an once-daily, first-in-class bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of patients with chronic lymphocytic leukemia, waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma and chronic graft-versus-host disease. Its products candidate in clinical development includes Imbruvica BTK inhibitor intended for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, graft versus host disease, mature B-cell non-hodgkin lymphomas, and solid tumors, among others. Pharmacyclics is headquartered in Sunnyvale, California, the US.
Pharmacyclics LLC premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed Products | Imbruvica |
Imbruvica (ibrutinib): | |
Chronic Lymphocytic Leukemia | |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Pharmacyclics LLC | Pharming Group NV | CTI BioPharma Corp | Ambrilia Biopharma Inc | Aphios Corp |
---|---|---|---|---|---|
Headquarters | United States of America | Netherlands | United States of America | Canada | United States of America |
City | Sunnyvale | Leiden | Seattle | Montreal | Woburn |
State/Province | California | - | Washington | Quebec | Massachusetts |
No. of Employees | - | 390 | 128 | - | - |
Entity Type | Private | Public | Private | Private | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Wulff-Erik von Borcke | President | Senior Management | 2015 | - |
Stefan Geldmeyer | Head - Finance and Infrastructure | Senior Management | 2016 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer